Market Overview

UPDATE: Deutsche Bank Downgrades Abbott Laboratories to Hold, Lowers PT

Related ABT
Markets Sell-Off After Malaysian Airline Crash In Ukraine
UPDATE: Morgan Stanley Reiterates On Abbott Laboratories As Growth and Margins Are Set To Continue
Will Congress Scuttle the AbbVie-Shire Merger? (Fox Business)

In a report published Friday, Deutsche Bank downgraded its rating on Abbott Laboratories (NYSE: ABT) from Buy to Hold, and lowered its price target from $70.00 to $33.00.

Deutsche Bank noted, “Effective January 2, real-way trading commenced for the ‘new Abbott' (ABT-$33.27) and newly spun AbbVie (ABBV-$34.83). With this note, we are establishing our formal estimates and price target for ‘new ABT'. From a fundamental perspective, we believe new Abbott is an attractive company as it is well-diversified from a product, geographic, and reimbursement risk perspective and has the potential for above peer growth. However, we believe the current share price captures this positive fundamental outlook and our revised price target for ‘new ABT' is $33 (old was $70). Given the limited upside, we now rate ‘new ABT' Hold (‘old ABT' was a Buy).”

Abbott Laboratories closed on Thursday at $33.29.

Posted-In: Deutsche BankAnalyst Color Downgrades Analyst Ratings

 

Most Popular

Related Articles (ABT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free